Cytodyn Inc (CYDY)

[justdafactss]

About Leronlimab (PRO 140)

The U.S. Food and Drug Administration (FDA) has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
https://www.globenewswire.com/news-release/2020/03/04/1994938/0/en/CytoDyn-Treats-First-Patient-with-Leronlimab-in-Phase-2-Trial-for-GvHD-under-Modified-Trial-Protocol.html